Please note that sales of Pfizer’s PFE RSV vaccine, Abrysvo, and GSK plc’s GSK RSV vaccine Arexvy also declined in the fourth quarter. This downtick can be attributed to the restrictive ...

Considering vaccines for infectious diseases, PFE's RSV vaccine (Abrysvo) is already approved and competing with MRNA's mRESVIA (mRNA-1345). PFE has a head start in contracts and market ...

The syndrome has cropped up as a side effect in trials for RSV vaccines like Pfizer’s Abrysvo and GSK’s Arexvy. The single case of Guillain-Barré syndrome in the mRNA-1403 trial is ...

PFE’s RSV vaccine Abrysvo is approved for older adults, as well as infants through maternal immunization. The vaccine is also approved for the prevention of lower respiratory tract disease (LRTD ...

mResvia’s top-line score comes in slightly lower than Arexvy and slightly above Abrysvo, they note – notwithstanding differences in study design – and will be weighed up against the ...

It's notable, however, that Arexvy's main rival in the RSV vaccine space – Pfizer's Abrysvo – held up much better in the third quarter, with sales slipping only around 5% to $356 million.

The term “going viral” describes content spreading quickly and broadly across social media. In 2016, Pinkfong, a South Korean entertainment company released a version of a youth song called Baby Shark ...